Cargando…

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Pejchinovski, Martin, Wang, Xueqi, Fu, Xuebin, Castelletti, Deborah, Watnick, Terry J., Arcaro, Alexandre, Siwy, Justyna, Mullen, William, Mischak, Harald, Serra, Andreas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882886/
https://www.ncbi.nlm.nih.gov/pubmed/29615724
http://dx.doi.org/10.1038/s41598-018-22938-x
_version_ 1783311544708235264
author Liu, Yang
Pejchinovski, Martin
Wang, Xueqi
Fu, Xuebin
Castelletti, Deborah
Watnick, Terry J.
Arcaro, Alexandre
Siwy, Justyna
Mullen, William
Mischak, Harald
Serra, Andreas L.
author_facet Liu, Yang
Pejchinovski, Martin
Wang, Xueqi
Fu, Xuebin
Castelletti, Deborah
Watnick, Terry J.
Arcaro, Alexandre
Siwy, Justyna
Mullen, William
Mischak, Harald
Serra, Andreas L.
author_sort Liu, Yang
collection PubMed
description Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling in rat and mouse PKD models. Dual mTOR/PI3K inhibition with NVP-BEZ235 abrogated these pro-proliferative signals and normalized kidney morphology and function by blocking proliferation and fibrosis. Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential treatment for ADPKD.
format Online
Article
Text
id pubmed-5882886
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58828862018-04-09 Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease Liu, Yang Pejchinovski, Martin Wang, Xueqi Fu, Xuebin Castelletti, Deborah Watnick, Terry J. Arcaro, Alexandre Siwy, Justyna Mullen, William Mischak, Harald Serra, Andreas L. Sci Rep Article Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling in rat and mouse PKD models. Dual mTOR/PI3K inhibition with NVP-BEZ235 abrogated these pro-proliferative signals and normalized kidney morphology and function by blocking proliferation and fibrosis. Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential treatment for ADPKD. Nature Publishing Group UK 2018-04-03 /pmc/articles/PMC5882886/ /pubmed/29615724 http://dx.doi.org/10.1038/s41598-018-22938-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Yang
Pejchinovski, Martin
Wang, Xueqi
Fu, Xuebin
Castelletti, Deborah
Watnick, Terry J.
Arcaro, Alexandre
Siwy, Justyna
Mullen, William
Mischak, Harald
Serra, Andreas L.
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title_full Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title_fullStr Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title_full_unstemmed Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title_short Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
title_sort dual mtor/pi3k inhibition limits pi3k-dependent pathways activated upon mtor inhibition in autosomal dominant polycystic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882886/
https://www.ncbi.nlm.nih.gov/pubmed/29615724
http://dx.doi.org/10.1038/s41598-018-22938-x
work_keys_str_mv AT liuyang dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT pejchinovskimartin dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT wangxueqi dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT fuxuebin dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT castellettideborah dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT watnickterryj dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT arcaroalexandre dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT siwyjustyna dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT mullenwilliam dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT mischakharald dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease
AT serraandreasl dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease